⏳ Fetching live dividend data...
Home › Calculator › CFRX Dividend Calculator 2026
ContraFect Corporation · NASDAQ
Price: $0.05 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in CFRX → $134226593101524.02M in 10 years · $10,912,731,146,465,364,000.00/month
ContraFect Corporation is a biotechnology firm operating at the clinical stage, dedicated to the discovery and development of innovative therapeutic proteins and antibodies. Its primary mission is to address life-threatening and drug-resistant infectious diseases within the United States. The company's most advanced candidate, Exebacase, a specialized enzyme known as a lysin, is currently undergoing Phase III clinical trials. This drug aims to treat bacteremia caused by Staphylococcus aureus. Beyond Exebacase, ContraFect is also progressing CF-296, an engineered lysin designed to combat invasive Staphylococcus aureus infections. These include challenging biofilm-related infections affecting prosthetic joints and indwelling medical devices, as well as osteomyelitis. Furthermore, CF-370, an investigational anti-bacterial therapy, has entered Phase 1 clinical trials. It targets a range of Pseudomonas aeruginosa infections, such as ventilator-associated pneumonia, bloodstream infections, complex urinary tract infections, and infections arising from surgery. In an effort to expand patient access, ContraFect has launched a program providing Exebacase for individuals with persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia who are also suffering from COVID-19. A licensing agreement with The Rockefeller University further supports its efforts to identify novel lysin therapeutic compounds effective against gram-negative pathogens. ContraFect Corporation was founded in 2008 and maintains its headquarters in Yonkers, New York.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CFRX position with:
Real after-tax yield depends on where you live and how you hold CFRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4000.00% | 3997.20% | $400,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3400.00% | 3397.20% | $340,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3200.00% | 3197.20% | $320,000 / yr |
| 🇬🇧 UK ISA | 0% | 4000.00% | 3997.20% | $400,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3650.00% | 3647.20% | $365,000 / yr |
| 🇨🇦 TFSA | 0% | 4000.00% | 3997.20% | $400,000 / yr |
| 🇨🇦 CA Taxable | 25% | 3000.00% | 2997.20% | $300,000 / yr |
| 🇦🇺 Super (pension) | 15% | 3400.00% | 3397.20% | $340,000 / yr |
| 🇦🇺 AU Taxable | 30% | 2800.00% | 2797.20% | $280,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2945.00% | 2942.20% | $294,500 / yr |
| 🇫🇷 FR Taxable | 30% | 2800.00% | 2797.20% | $280,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CFRX pays quarterly — 4 times per year. Next ex-div: TBD.
How CFRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CFRX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2023-02-14 | 25,000 | $5.04 | $126.0K | ||
| A-Award | 2022-05-17 | 42,000 | $3.35 | $140.7K | ||
| A-Award | 2022-05-17 | 42,000 | $3.35 | $140.7K | ||
| A-Award | 2022-05-17 | 42,000 | $3.35 | $140.7K | ||
| A-Award | 2022-05-17 | 42,000 | $3.35 | $140.7K | ||
| A-Award | 2022-05-17 | 42,000 | $3.35 | $140.7K | ||
| A-Award | 2022-05-17 | 42,000 | $3.35 | $140.7K | ||
| A-Award | 2022-05-17 | 42,000 | $3.35 | $140.7K | ||
| A-Award | 2022-02-15 | 500,000 | $3.33 | $1.67M | ||
| A-Award | 2022-02-15 | 165,000 | $3.33 | $549.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CFRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
ContraFect Corporation (CFRX) is currently trading at $0.05, 100% below its 52-week high. The current dividend yield is 4000.00% based on an annual payout of $2.00 per share.
ContraFect Corporation (CFRX) is a healthcare stock currently trading at $0.05 with a dividend yield of 4000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →